Novo Nordisk and Eli Lilly spent years racing to develop injectable weight-loss drugs that cost more than a used Honda Civic. Now they're locked in a thrilling competition to create the exact same drugs in pill form. For seniors. With Medicare picking up the tab.
The strategic brilliance here is flawless. Convince Medicare to cover expensive pills that make old people less hungry. The same Medicare that's perpetually one budget crisis away from insolvency. The same seniors who currently choose between prescriptions and groceries. But sure, let's add GLP-1 pills to the mix.
Both companies are "preparing their pitch" to this demographic. The pitch presumably goes something like this: "You know what you need at seventy-three? A pharmaceutical rivalry playing out in your bloodstream."
Retail traders will naturally interpret this headline as their signal to go all-in on both stocks. Because nothing screams "investment thesis" like two pharmaceutical giants fighting over government reimbursement rates. They'll buy calls on Novo. They'll buy calls on Lilly. They'll create some deranged spreadsheet comparing the companies' pipeline data that they found on Reddit.
The technical analysis couldn't be clearer. Both stocks will either go up, down, or sideways based on factors that have absolutely nothing to do with which company makes a slightly better pill that does the same thing as the injectable version.
Medicare coverage means guaranteed revenue. It also means guaranteed price negotiations with the federal government. Retail traders will focus on the first part. They always do.
The real winner here is whichever company convinces more geriatric patients that taking a daily pill is worth whatever catastrophic side effect makes it onto page seventeen of the warning label, right after the part about thyroid tumors in rats.
Photo by on Unsplash
Leave a Comment